# US 8,784,795 B2 · Methods for determining personalized treatment compositions for prostate cancer and breast cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,784,795 B2 - Document ID: US8784795B2 - Status: Granted - Kind: B2 - Application number: 13/935,355 - Filed: 2013-07-03 - Published: 2014-01-09 - Granted: 2014-07-22 - Earliest claimed: 2012-07-05 - Assignees: Caldera Health Limited - Applicants: Caldera Health Ltd. - Inventors: James D. Watson; Richard Llewellyn Sydney Forster - Web page: https://patentgrep.com/patent/US8784795B2 ## CPC - G01N 33/5047: {Cells of the immune system} - A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin - A61K 31/497: containing further heterocyclic rings - A61K 38/193: {Colony stimulating factors [CSF]} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 35/00: Antineoplastic agents - G01N 33/57515: of the breast - G01N 33/57555: of the prostate - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from two different classes of compounds. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period. ## Claims ### Claim 1 A method for determining the efficacy of a candidate anti-prostate cancer therapy for a patient diagnosed with prostate cancer wherein the candidate anti-prostate cancer therapy comprises an immune cell activating agent and an antigen display enhancing agent that is able to stimulate or enhance the presentation of a cancer-specific antigen on the surface of prostate cancer cells, the method comprising: (a) incubating immune cells obtained from the patient with the immune cell activating agent to provide activated immune cells; (b) incubating prostate cancer cells from an established prostate cancer cell line with the antigen display enhancing agent, thereby providing treated prostate cancer cells; (c) contacting the activated immune cells with the treated prostate cancer cells; and (d) determining the ability of the activated immune cells to kill the treated prostate cancer cells, wherein the ability of the activated immune cells to kill the treated prostate cancer cells is indicative of the efficacy of the candidate anti-prostate cancer therapy. ### Claim 2 (depends on 1) The method of claim 1, wherein the immune cell activating agent activates cells of the innate immune system. ### Claim 3 (depends on 1) The method of claim 1, wherein the immune cell activating agent is selected from the group consisting of granulocyte-macrophage colony stimulating factor (GM-CSF); granulocyte colony stimulating factor (G-CSF); inactivated mycobacterial species components of bacterial cell walls that have adjuvant activity; and antibodies, or antigen-binding fragments thereof, that are agonists or antagonists of CD137, CD152, CD95 or CD178. ### Claim 4 (depends on 1) The method of claim 1, wherein the antigen display enhancing agent activates an apoptotic process in the prostate cancer cells. ### Claim 5 (depends on 1) The method of claim 1, wherein the antigen display enhancing agent causes perturbation of cell lipid and cholesterol metabolism thereby altering membrane structures on the prostate cancer cells. ### Claim 6 (depends on 1) The method of claim 1, wherein the antigen display enhancing agent is selected from the group consisting of: lipid targeting compounds; ketoconazole; itraconazole; fluconazole; alkylglycerophosphocholine; edelfosine; ilmofosine; miltefosine; amphotericin B; compounds that lower testosterone or estrogen levels; compounds that block luteinizing hormone-releasing factor; goselerin acetate; leuprolide; compounds that block testosterone action; bicalutamide; flutamide; dutasteride; finasteride; thalidomide; celecoxib; candesartan; candesartan cilexetil phenylbutyrate; atrasentan; captopril; isotretinoin; tretinoin; rosiglitazone; pioglitazone; tamoxifen; aromatases; non-steroidal aromatase inhibitors; letrozole; anastrozole; steroidal aromatase inhibitors; exemestane; selective estrogen receptor down-regulators (SERDs); fulvestrant; everolimus; compounds that block dihydroxy-testosterone production; 5α- and 5β-reductase inhibitors; abitraterone; trastuzumab; chemotherapeutic compounds; docetaxel; gemcitibine; bisphosphonates; pamidronate; and zoledronic acid. ### Claim 7 (depends on 1) The method of claim 1, wherein the immune cells are isolated from a biological sample selected from the group consisting of: blood; and lymph node tissue. ### Claim 8 A method for monitoring the efficacy of an anti-prostate cancer therapy in a patient diagnosed with prostate cancer, wherein the anti-prostate cancer therapy comprises an immune cell activating agent and an antigen display enhancing agent that is able to stimulate or enhance the presentation of a cancer-specific antigen on the surface of prostate cancer cells, the method comprising: (a) incubating a first plurality of immune cells obtained from the patient prior to treatment with the immune cell activating agent to provide activated immune cells; (b) incubating prostate cancer cells from an established prostate cancer cell line with the antigen display enhancing agent, thereby providing treated prostate state cancer cells; (c) contacting the activated immune cells with the treated prostate cancer cells and determining the ability of the activated immune cells to kill the treated prostate cancer cells; and (d) repeating steps (b)-(c) with a second plurality of immune cells obtained from the patient at a subsequent time interval following administration of the anti-prostate cancer therapy, wherein a reduction in the ability of activated immune cells prepared from the second plurality of immune cells to kill the treated prostate cancer cells compared to the ability of activated immune cells prepared from the first plurality of immune cells to kill the treated prostate cancer cells is indicative of a reduction in the efficacy of the anti-prostate cancer therapy. ### Claim 9 (depends on 8) The method of claim 8, wherein the immune cell activating agent activates cells of the innate immune system. ### Claim 10 (depends on 8) The method of claim 8, wherein the immune cell activating agent is selected from the group consisting of: granulocyte-macrophage colony stimulating factor (GM-CSF); granulocyte colony stimulating factor (G-CSF); inactivated mycobacterial species; components of bacterial cell walls that have adjuvant activity; and antibodies, or antigen-binding fragments thereof, that are agonists or antagonists of CD137, CD152, CD95 or CD178. ### Claim 11 (depends on 8) The method of claim 8, wherein the antigen display enhancing agent activates an apoptotic process in the prostate cancer cells. ### Claim 12 (depends on 8) The method of claim 8, wherein the antigen display enhancing agent causes perturbation of cell lipid and cholesterol metabolism thereby altering membrane structures on the prostate cancer cells. ### Claim 13 (depends on 1) The method of claim 1, wherein the antigen display enhancing agent is selected from the group consisting of: lipid targeting compounds; ketoconazole; itraconazole; fluconazole; alkylglycerophosphocholine; edelfosine; ilmofosine; miltefosine; amphotericin B; compounds that lower testosterone or estrogen levels; compounds that block luteinizing hormone-releasing factor; goselerin acetate; leuprolide; compounds that block testosterone action; bicalutamide; flutamide; dutasteride; finasteride; thalidomide; celecoxib; candesartan; candesartan cilexetil phenylbutyrate; atrasentan; captopril; isotretinoin; tretinoin; rosiglitazone; pioglitazone; tamoxifen; aromatases; non-steroidal aromatase inhibitors; letrozole; anastrozole; steroidal aromatase inhibitors; exemestane; selective estrogen receptor down-regulators (SERDs); fulvestrant; everolimus; compounds that block dihydroxy-testosterone production; 5α- and 5β-reductase inhibitors; abitraterone; trastuzumab; chemotherapeutic compounds; docetaxel; gemcitibine; bisphosphonates; pamidronate; and zoledronic acid. ### Claim 14 (depends on 8) The method of claim 8, further comprising monitoring levels of at least one prostate cancer specific biomarker and/or the levels of at least one marker of immune health in the patient. ### Claim 15 (depends on 8) The method of claim 8, wherein the immune cells are isolated from a biological sample selected from the group consisting of: blood; and lymph node tissue.